Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Acquisition of Lideta Hälsovård
Mandate

Acquisition of Lideta Hälsovård

November 10, 2017 M&A

Vinge is advising Nordstjernan in conjunction with the acquisition of a majority of the shares in Lideta Hälsovård.

Lideta conducts primary care via 15 centres in Stockholm and in southern Sweden. The company has grown quickly since it was founded in 2001 by doctor Simon Larsson and currently has 93 000 listed patients, 350 employees and a turnover of approximately MSEK 500.

The transaction is conditional upon approval by the relevant competition authorities, which is expected during the fourth quarter of 2017.

Vinge’s team consisted of partners Johan Winnerblad and Kristina Ekberg, associates Samra Baytar, Johanna Wiberg and Marion Kronberg. Grant McKelvey and Xandra Ståhlberg provided competition law advice.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026